Blog

 

Opko Acquires Prolor for $480 M

OPKO Health, Inc. (NYSE: OPK) has signed a definitive merger agreement under which OPKO will acquire Prolor in an all-stock transaction. Under the terms of the agreement, which has been approved by the boards of directors of both companies, holders of PROLOR common stock will receive 0.9951 shares of OPKO...
Read more

Can-Fite Completes Phase III Dry Eye Enrollment

Can-Fite, currently traded OTC in the US has filed for a NASDAQ listing. The company’s subsidiary, OphthaliX Inc., recently announced that it has completed patient enrollment for a Phase 3 clinical study of CF101 for the treatment of Dry Eye Syndrome (DES). The randomized, double-masked study is conducted in the...
Read more

ProCognia Deals With SBH and Health Canada

Glycoanalysis developer ProCognia (TASE:PRCG) has signed a strategic collaboration and co-promotion agreement with Boston-based biotechnology services provider SBH Sciences Inc. The companies provide complementary services to the biopharmaceutical and pharmaceutical industries, and they will offer joint sales and marketing activities for these services. SBH Sciences will also serve as a...
Read more

Atox Bio Stops Flesh Eating Bacteria

Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as “flesh eating bacteria” demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial...
Read more

Intec Pharma Gets Michael Fox Grant

Intec Pharma has received a grant from The Michael J. Fox Foundation for Parkinson’s Research in the amount of $705,000. The grant will finance a pre-clinical safety trial using the company’s delayed release Accordion Pill Carbidopa/Levodopa developed for the treatment of Parkinson’s disease. Intec Pharma has completed successfully Phase II...
Read more